Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers
Status:
Terminated
Trial end date:
2020-03-12
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, multi-center study to assess safety and determine the
recommended phase 2 dose (RP2D) of ACTR T cell product (ACTR707 or ACTR087) in combination
with trastuzumab, following lymphodepleting chemotherapy in subjects with HER2-positive
advanced malignancies.